26 July 2019
EMA/PDCO/366850/2019
Inspections, Human Medicines Pharmacovigilance and Committees Division

Paediatric Committee (PDCO)

Minutes of the meeting on 25-28 June 2019

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

25 June 2019, 14:00- 19:00, room 2D

26 June 2019, 08:30- 19:00, room 2D

27 June 2019, 08:30- 19:00, room 2D

28 June 2019, 08:30- 13:00, room 2D

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by Applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Note on access to documents

Some documents mentioned in these minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda for 25-28 June 2019 was adopted and published on the EMA website.

1.3. Adoption of the minutes

The minutes of 27-29 May were adopted and will be published on the EMA website.

2. Opinions

Some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. 6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4 triazol-3-yl)phenyl]amino}-N-(2H3)methylpyridazine-3-carboxamide - EMEA-002350-PIP01-18

Bristol-Myers Squibb International Corporation; Treatment of psoriasis / Treatment of moderate to severe plaque psoriasis in paediatric patients 6 years of age and older

Day 120 Opinion

Dermatology

Summary of committee discussion:

The PDCO discussed this procedure on D120. A positive Opinion was adopted on this PIP for the treatment of psoriasis.

2.1.2. EMEA-002464-PIP01-18

Eli Lilly and Company; Treatment of atopic dermatitis / Treatment of patients with moderate-to-severe atopic dermatitis

Day 120 Opinion

Dermatology

Summary of committee discussion:

The PDCO discussed this application on D120. A positive Opinion was adopted.

2.1.3. Oxalobacter formigenes strain HC-1 - Orphan - EMEA-000370-PIP02-18

OxThera AB; ICD10-E72.53 Hyperoxaluria / Treatment of primary hyperoxaluria

Day 120 Opinion

Endocrinology-Gynaecology-Fertility-Metabolism / Uro-nephrology

Summary of committee discussion:

Based on the assessment of this application, and in line with the outcome of the Day 90 discussion, the PDCO agreed with a PIP for Oxalobacter formigenes for the treatment of primary hyperoxaluria in paediatric patients from birth to less than 18 years of age.

2.1.4. Humanized anti-CD19, Fc engineered, monoclonal antibody - Orphan - EMEA-002414-PIP01-18

Xencor, Inc.; Immunoglobulin G4-related disease / Treatment of adults, adolescents and children (> 23 months of age) with immunoglobulin G4-related disease

Day 120 Opinion

Action: For adoption

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the assessment of this application and further information by the Applicant, the PDCO adopted a positive Opinion for the treatment of immunoglobulin G4-related disease.

2.1.5. Vedolizumab - EMEA-000645-PIP03-18

Takeda Pharma A/S; ICD-9-CM 279.51 / ICD-10-CM D89.810 - Other disorders involving the immune mechanism, not elsewhere classified: acute graft-versus-host disease

Day 120 Opinion

Immunology-Rheumatology-Transplantation / Gastroenterology-Hepatology

Summary of committee discussion:

A positive Opinion was adopted for this PIP for prevention of acute graft-versus host disease in children.

2.1.6. Bulevirtide - Orphan - EMEA-002399-PIP01-18

MYR GmbH; Chronic hepatitis D infection

Day 120 Opinion

Infectious Diseases

Summary of committee discussion:

In conclusion, the PDCO adopted a positive Opinion on the paediatric plan proposed by the Applicant.
All measures were fully deferred. Recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein - Orphan - EMEA-002435-PIP01-18

PTC Therapeutic International Limited; Aromatic L-amino acid decarboxylase (AADC) deficiency / Treatment of aromatic L-amino acid decarboxylase (AADC) deficiency

Day 120 Opinion

Neurology

Summary of committee discussion:

The PDCO discussed this procedure at Day 120 during the June 2019 plenary meeting. The PDCO adopted a positive Opinion.

2.1.7. Botulinum toxin type A - EMEA-002521-PIP01-18

Allergan Pharmaceuticals International Limited; Muscle-induced wrinkles

Day 60 Opinion

Dermatology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the Applicant's request for a waiver. The PDCO recommended granting a waiver for Botulinum toxin type A for all subsets of the paediatric population (0 to 18 years of age) in the condition of skin wrinkling.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the Applicant from considering a development in the paediatric population in indications where there is a paediatric need.

Endocyte, Inc.; Prostate-specific membrane antigen (PSMA)-expressing metastatic prostate cancer

Day 60 Opinion

Diagnostic / Oncology

Summary of committee discussion:

The PDCO discussed this procedure at Day 60 during the June 2019 plenary meeting. The PDCO adopted a positive Opinion at Day 60 for a product specific-waiver on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

2.1.9. Human chorionic gonadotrophin - EMEA-002547-PIP01-19

Regulis Consulting Europe Ltd; Infertility / Assisted reproductive technology (ART) program such as in vitro fertilisation, anovulatory or oligo-ovulatory women

Day 60 Opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agreed with the Applicant's request for a waiver. The PDCO recommended granting a waiver for human chorionic gonadotrophin for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'treatment of female infertility'.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the Applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.10. Mifepristone - EMEA-001437-PIP02-19

Laboratorios Litaphar S.L.; Endometriosis

Day 60 Opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for mifepristone for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'treatment of endometriosis'.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the Applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population

are available even if a waiver has been granted in another condition.

2.1.11. Istradefylline - EMEA-002540-PIP01-18

Kyowa Kirin Limited; Parkinson's disease

Day 60 Opinion

Neurology

Summary of committee discussion:

Based on the assessment of this application the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for istradefylline for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'treatment of Parkinson's disease' on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2.1.12. EMEA-002575-PIP01-19

Blueprint Medicines (Netherlands) B.V.; Treatment of lung carcinoma (small cell and non-small cell carcinoma)

Day 60 Opinion

Oncology

Summary of committee discussion:

The PDCO discussed this procedure at Day 60 during the June 2019 plenary meeting. This product is an oral, selective inhibitor of the rearranged during transfection (RET) receptor tyrosine kinase (RTK).
The Applicant is requesting a product-specific waiver for the treatment of lung carcinoma (small cell and non-small cell carcinoma). The Committee agreed a positive Opinion at Day 60 for a product-specific waiver on the grounds that the medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients because studies in patients with lung cancer would not be feasible.

2.1.13. EGFR-cMET bispecific antibody - EMEA-002573-PIP01-19

Janssen-Cilag International N.V.; Treatment of lung carcinoma (small cell and non-small cell carcinoma)

Day 60 Opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed this procedure in line with the D30 discussion, agreeing on a product specific waiver for this EGFR-cMET bispecific antibody, for the proposed condition of 'treatment of lung carcinoma', on the ground that the disease does not occur in children.

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for EGFR-cMET bispecific antibody for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'treatment of lung carcinoma'.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.14. Tafasitamab - Humanised Fc engineered monoclonal antibody against CD19 for the treatment of diffuse large B-cell lymphoma - Orphan - EMEA-002499-PIP02-19

MorphoSys AG; Diffuse large B-Cell lymphoma

Day 60 Opinion

Oncology

Summary of committee discussion:

A positive Opinion was concluded for this product, supporting a product specific waiver based on the ground of lack of significant therapeutic benefit.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a product specific waiver based on the ground of lack of significant therapeutic benefit. The PDCO recommends granting a waiver for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'diffuse large B-cell lymphoma'.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the Applicant from considering a development in the paediatric population in indications where there is a paediatric need. The PDCO identified acute lymphoblastic leukaemia as an unmet need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.15. Ciclosporin - EMEA-002491-PIP02-19

Sun Pharmaceutical Industries Europe BV; Treatment of dry eye disease

Day 60 Opinion

Ophthalmology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for ciclosporin for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'treatment of dry eye disease' on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.16. Anti-neonatal Fc receptor human monoclonal antibody - EMEA-002559-PIP01-19

Momenta Pharmaceuticals, Inc.; Haemolytic disease of the foetus and newborn (HDFN)

Day 60 Opinion

Other

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for anti-neonatal Fc receptor human monoclonal antibody for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'prevention of haemolytic disease of the foetus and newborn (HDFN)'.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.17. Norethisterone acetate / estradiol / relugolix - EMEA-002428-PIP02-18

Myovant Sciences Ireland Limited; endometriosis / treatment of symptoms associated with endometriosis

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO recommends granting a waiver on its own motion for norethisterone acetate / estradiol / relugolix for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'treatment of endometriosis'.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

2.2.1. Etravirine - EMEA-C-000222-PIP01-08-M09

Janssen-Cilag International NV; Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:
• EMEA-C2-000222-PIP01-08-M05
The PDCO adopted on 28 June 2019 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0121/2019) of 17 April 2019.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

Blue Earth Diagnostics Ireland Ltd; Diagnosis of amino acid metabolism in solid malignant tumours / Diagnosis of primary and recurrent brain tumours

Day 60 Opinion

Diagnostic / Oncology

Summary of committee discussion:

The Committee therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0256/2015 of 30 October 2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.2. Saxagliptin - EMEA-000200-PIP01-08-M08

AstraZeneca AB; E11 Type 2 Diabetes / Treatment of type 2 Diabetes

Day 60 Opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

During its June plenary meeting, the PDCO adopted a positive Opinion on the PIP modification request for the DDP4 (dipeptidylpeptidase 4) inhibitor saxagliptin for the treatment of type 2 diabetes in children from 10 to less than 18 years of age.
The PDCO adopted a favourable Opinion on the modification of the agreed PIP, in line

with the above, as set in the Agency's latest decision (P/0051/2017 of 17/03/2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.3. Belatacept - EMEA-000157-PIP01-07-M04

Bristol-Myers Squibb Pharma EEIG; Prevention of rejection of transplanted kidney in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in paediatric patients at least 12 years of age and with a stable renal transplant for at least 6 months, who convert to a calcineurin inhibitor (CNI) -free maintenance immunosuppressive regimen.

Day 60 Opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The proposed change was considered acceptable.
In conclusion, the PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0002/2017 of 12 January 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.4. Ixekizumab - EMEA-001050-PIP02-18-M01

Eli Lilly Nederland B.V.; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis) / Children with juvenile idiopathic arthritis subtypes of enthesitis-related arthritis (including juvenile onset axial spondyloarthritis (JoAS)) and juvenile psoriatic arthritis.

Day 60 Opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0352/2018 of 19/11/2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.5. Recombinant human monoclonal antibody to GM-CSF - EMEA-001882-PIP02-16-M01

GlaxoSmithKline Trading Services Limited; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis) / Treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older / Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older

Day 60 Opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0272/2017 of 4/10/2017).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.6. Delamanid - Orphan - EMEA-001113-PIP01-10-M06

Otsuka Pharmaceutical Development & Commercialisation Europe GmbH; Treatment of multi drug resistant tuberculosis

Day 60 Opinion

Infectious Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0269/2016 of 07/10/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.7. Eslicarbazepine acetate - EMEA-000696-PIP02-10-M06

BIAL - Portela & Ca, SA; Treatment of epilepsy with partial onset seizures / Treatment of epilepsy with partial onset seizures with eslicarbazepine acetate (ESL) as adjunctive therapy. Treatment of epilepsy with partial onset seizures with eslicarbazepine acetate (ESL) as monotherapy

Day 60 Opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that some of the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0015/2015 of 30 January 2015).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.8. Eteplirsen - Orphan - EMEA-001722-PIP01-14-M02

Sarepta Therapeutics Ireland Limited; Duchenne muscular dystrophy

Day 60 Opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that some of the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0279/2016 of 7 October 2016).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.9. Lasmiditan - EMEA-002166-PIP01-17-M02

Eli Lilly and Company Limited; Migraine with and without aura

Day 60 Opinion

Neurology

Summary of committee discussion:

Therefore PDCO considered that the proposed changes could be accepted and adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0358/2018 of 7/12/2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.10. Bosutinib - EMEA-000727-PIP01-09-M03

Pfizer Europe MA EEIG; Treatment of chronic myeloid leukemia (CML) / Treatment of chronic, accelerated or blast phase CML with resistance or intolerance to prior TKI therapy / Treatment of newly-diagnosed chronic phase of Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML)

Day 60 Opinion

Oncology

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0325/2016 of 2 December 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

Jazz Pharmaceuticals Ireland Limited; Acute myeloid leukaemia / Treatment of acute

myeloid leukaemia

Day 60 Opinion

Oncology

Summary of committee discussion:

In conclusion, the PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0388/2018 of 7 December 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.12. Ixazomib - Orphan - EMEA-001410-PIP02-17-M02

Takeda Pharm A/S; Treatment of lymphoid malignancies (excluding multiple myeloma) / Treatment of multiple myeloma (MM) / Treatment of adult patients with newly diagnosed multiple myeloma (NDMM) / Treatment of paediatric patients diagnosed with relapsed precursor B-acute lymphoblastic leukemia (ALL) or T-ALL

Day 60 Opinion

Oncology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0376/2018 of 07/12/2018.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.13. Selumetinib - Orphan - EMEA-001585-PIP01-13-M03

AstraZeneca AB; Treatment of thyroid cancer / Treatment of neurofibromatosis type 1 (NF1) / Selumetinib in combination with adjuvant radioactive iodine therapy is indicated for the treatment of adolescents newly diagnosed with differentiated thyroid cancer who are at high risk of primary treatment failure / Selumetinib is indicated for the treatment of inoperable NF1 related plexiform neurofibroma in children and adolescents

Day 60 Opinion

Oncology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the majority of the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0072/2018 of 16/03/2018).

2.3.14. Palonosetron / fosnetupitant - EMEA-001198-PIP03-17-M02

Helsinn Birex Pharmaceuticals Limited; Prevention of chemotherapy-induced nausea and vomiting

Day 60 Opinion

Other

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0344/2018 of 08 November 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion

2.3.15. Octenidine (dihydrochloride) - EMEA-001514-PIP01-13-M01

Cassella-med GmbH & Co. KG; Treatment of upper respiratory tract infections / Treatment of sore-throat due to infectious pharyngitis

Day 60 Opinion

Oto-rhino-laryngology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0093/2016 of 23 March 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.16. Reslizumab - EMEA-001202-PIP02-13-M03

Teva Pharmaceuticals Europe; Treatment of asthma / Add-on treatment to reduce exacerbations, relieve symptoms and improve lung function in paediatric patients from 6 to less than 18 years of age with inadequately controlled severe asthma who have a blood eosinophil count greater than or equal to 300 µL

Day 60 Opinion

Pneumology - Allergology

Summary of committee discussion:

The PDCO discussed the Applicant's responses after Day 30 and considered that the proposal for further development of reslizumab in adolescents was not optimal.
The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0010/2018 of 30 January 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.17. Tezepelumab - EMEA-001613-PIP01-14-M03

AstraZeneca AB; Treatment of asthma / Tezepelumab is indicated as add-on maintenance treatment of patients with severe asthma aged 5 years and older.

Day 60 Opinion

Pneumology - Allergology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0365/2018 of 7 December 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.18. Mirabegron - EMEA-000597-PIP02-10-M07

Astellas Pharma Europe B.V.; Treatment of idiopathic overactive bladder / Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome

Day 60 Opinion

Uro-nephrology

Summary of committee discussion:

Having assessed the proposed modification of the paediatric investigation plan, the Committee had a split vote in favour of a negative Opinion where no majority could be reached.

Sixteen members voted in favour of a negative Opinion whilst eleven members had divergent views.

The Norwegian PDCO member was not in agreement with the negative Opinion.

Therefore, in line with the PDCO Rules of Procedure (EMA/348440/2008 Rev.1) where 'in the event of no majority position in favour of the concerned Opinion, the Committee's opinion is deemed to be negative', the PDCO adopted a negative Opinion.

2.4. Opinions on Re-examinations

2.4.1. Genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII - Orphan - EMEA-002472-PIP02-19

Krystal Biotech, Inc.; Dystrophic epidermolysis bullosa

Day 30 Opinion

Dermatology

Summary of committee discussion:

The Applicant submitted a request for re-examination of the PIP opinion for this genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII for the 'treatment of dystrophic epidermolysis bullosa (DEB)'. In conclusion, the PDCO confirmed its negative Opinion and considered that the Applicant should revise their plan via a new PIP submission taking into account the comments provided in the summary report.

2.5. Opinions on Review of Granted Waivers

No items

2.6. Finalisation and adoption of Opinions

No items

2.7. Partial Compliance Checks completed by EMA

For the following partial compliance checks, no need to refer them to PDCO Committee for discussion, were identified by the PME coordinator and PDCO Rapporteur. The PDCO has been informed in writing.

2.7.1. Ponesimod - EMEA-C1-000798-PIP01-09-M01

Janssen-Cilag International NV; Treatment of multiple sclerosis

Day 30 letter

Other / Neurology

Summary of committee discussion:

The study is hereby confirmed to be compliant as set out in the EMA's Decision (P/0128/2018) of 11/04/2018.
The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

2.7.2. Peanut (arachis hypogaea) allergen powder (previously known as Peanut flour) - EMEA-C1-001734-PIP01-14-M04

Aimmune Therapeutics Netherlands B.V.; Treatment of peanut allergy

Day 30 letter

Pneumology - Allergology

Summary of committee discussion:

The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

The PDCO has been informed about the outcome.

3. Discussion of applications

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Birch bark extract - Orphan - EMEA-001299-PIP03-17

Amryt Research Limited; Treatment of epidermolysis bullosa

Day 90 discussion

Dermatology

3.1.2. Trifarotene cream HE1 - EMEA-001492-PIP02-18

Lamellar ichthyosis / Treatment of lamellar ichthyosis

Day 90 discussion

Dermatology

3.1.3. Levonorgestrel - EMEA-002474-PIP02-18

Contraception

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.4. Tirzepatide - EMEA-002360-PIP01-18

Type 2 diabetes mellitus / Treatment of Type 2 diabetes mellitus

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.5. EMEA-002448-PIP01-18

Treatment of non-alcoholic steatohepatitis (NASH) / Treatment of NASH with moderate to severe liver fibrosis

Day 90 discussion

Gastroenterology-Hepatology

3.1.6. Bimekizumab - EMEA-002189-PIP02-18

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis) / Treatment of JIA (enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA)) in patients from ≥2 years to <18 years of age

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.7. Liposomal ciclosporin A (L-CsA) - Orphan - EMEA-002344-PIP02-18

Breath Therapeutics GmbH; Treatment of bronchiolitis obliterans syndrome (BOS)

Day 90 discussion

Immunology-Rheumatology-Transplantation

Prevention of influenza /Treatment of influenza / Treatment of influenza type A/B in otherwise healthy, high risk and hospitalised patients / Prevention (post-exposure prophylaxis) of influenza type A/B. Reduction of transmission of influenza type A/B.

Day 90 discussion

Infectious Diseases

3.1.9. Equine immunoglobulin F(ab')2 fragments targeting Shiga toxin - Orphan - EMEA-002444-PIP02-18

Chemo Research, S.L.; Prevention of Shiga-toxin producing *Escherichia coli* haemolytic uremic syndrome

Day 90 discussion

Infectious Diseases

3.1.10. Eptinezumab - EMEA-002243-PIP01-17

Prevention of migraine headaches / Prophylaxis of migraine

Day 90 discussion

Neurology

3.1.11. Fosmetpantotenate - Orphan - EMEA-002036-PIP01-16

Retrophin Europe Limited; Treatment of pantothenate kinase associated neurodegeneration (PKAN)

Day 90 discussion

Neurology

Tesaro UK Ltd; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid malignancies) / The combination therapy is for the treatment of patients ≥6 months to <18 years of age who have been diagnosed with recurrent solid tumours that exhibit a breast cancer susceptibility gene (BRCA)ness mutational signature (mutational signature 3)

Day 90 discussion

Oncology

3.1.13. Aldesleukin - EMEA-002492-PIP01-18

Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoetic, and lymphoid tissue) / In combination with nivolumab (or with nivolumab and ipilimumab), treatment of a relapsed or refractory paediatric malignant solid tumour in paediatric patients less than 18 years old / In combination with nivolumab (or with nivolumab and ipilimumab), treatment of patients with unresectable or metastatic melanoma in the age group from 12 to less than 18 years old

Day 90 discussion

Oncology

3.1.14. Pegvorhyaluronidase alfa - Orphan - EMEA-001883-PIP03-17

Halozyme Inc; Treatment of solid malignant tumours (except central nervous system tumours, haematopoietic and lymphoid tissue tumours) / Pegvorhyaluronidase alfa is indicated in combination with cytotoxic cancer therapies for the treatment of paediatric patients aged from birth to less than 18 years with relapsed or refractory solid tumours that accumulate high levels of hyaluronan

Day 90 discussion

Oncology

3.1.15. Anti PD-1 monoclonal antibody - EMEA-002463-PIP01-18

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid malignancies) / The combination therapy is for the treatment of patients ≥6 months to <18 years of age who have been diagnosed with recurrent solid tumours that exhibit a breast cancer susceptibility gene (BRCA)ness mutational signature (mutational signature 3)

Day 90 discussion

Oncology

3.1.16. EMEA-002433-PIP01-18

Treatment of severe asthma in patients 6 year-old and above as an add-on therapy of standard of care

Day 90 discussion

Pneumology - Allergology

3.1.17. Remimazolam - EMEA-001880-PIP02-19

Sedation during medical procedures / General anaesthesia and post-operative sedation up to 24h, sedation in the intensive care unit (ICU) / Sedation for short procedures

Day 60 discussion

Anaesthesiology

3.1.18. EMEA-002568-PIP01-19

Psoriasis / Treatment of moderate to severe chronic plaque-type psoriasis in children and adolescents who are candidates for systemic therapy

Day 60 discussion

Dermatology

3.1.19. Hydrogen peroxide - EMEA-001884-PIP03-18

Treatment of common warts (verrucae vulgaris) / Topical treatment to remove common warts (verrucae vulgaris)

Day 60 discussion

Dermatology

3.1.20. Dupilumab - EMEA-001501-PIP04-19

Treatment of eosinophilic esophagitis

Day 60 discussion

Gastroenterology-Hepatology

3.1.21. CD34+ enriched cells from patients with Fanconi anemia subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the FANCA gene - Orphan - EMEA-002578-PIP01-19

Rocket Pharmaceuticals, Inc.; Treatment of Fanconi anaemia subtype A

Day 60 discussion

Haematology-Hemostaseology

3.1.22. Probenecid / sulopenem etzadroxil - EMEA-002602-PIP01-19

Urinary tract infections / Abdominal and gastrointestinal infections / Uncomplicated urinary tract infections / Complicated intra-abdominal infections / Complicated urinary

tract infections

Day 60 discussion

Infectious Diseases

3.1.23. Sulopenem - EMEA-002478-PIP01-18

Urinary tract Infections / Abdominal and gastrointestinal infections / Uncomplicated urinary tract infections / Complicated intra-abdominal infections / Complicated urinary tract infections

Day 60 discussion

Infectious Diseases

3.1.24. Pracinostat - Orphan - EMEA-002567-PIP01-19

Helsinn Birex Pharmaceuticals limited; Acute Myeloid Leukemia

Day 60 discussion

Oncology

3.1.25. Budesonide - Orphan - EMEA-002500-PIP01-18

Calliditas Therapeutics AB; Primary IgA nephropathy

Day 60 discussion

Uro-nephrology

3.1.26. Nebivolol / zofenopril - EMEA-002593-PIP01-19

Treatment of essential hypertension

Day 30 discussion

Cardiovascular Diseases

3.1.27. Ramipril / rosuvastatin - EMEA-002569-PIP01-19

Treatment of cardiovascular disease

Day 30 discussion

Cardiovascular Diseases

3.1.28. Dihomo-γ-linolenic acid (DGLA) - EMEA-002364-PIP03-19

Treatment of atopic dermatitis / Treatment of moderate to severe atopic dermatitis

Day 30 discussion

Dermatology

3.1.29. Lebrikizumab - EMEA-002536-PIP01-18

Treatment of atopic dermatitis

Day 30 discussion

Dermatology

3.1.30. Deoxycytidine - Orphan - EMEA-002513-PIP01-18

Modis Therapeutics, Inc.; Treatment of thymidine kinase 2 deficiency

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.31. Deoxythymidine - Orphan - EMEA-002624-PIP01-19

Modis Therapeutics, Inc.; Treatment of thymidine kinase 2 deficiency

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.32. Pegcetacoplan - Orphan - EMEA-002600-PIP01-19

Apellis Ireland Limited; Paroxysmal nocturnal haemoglobinuria

Day 30 discussion

Haematology-Hemostaseology

3.1.33. Rivipansel sodium - Orphan - EMEA-002596-PIP01-19

Pfizer Europe MA EEIG; Treatment of sickle cell disease / Treatment of vaso-occlusive crisis in patients with sickle cell disease

Day 30 discussion

Haematology-Hemostaseology

3.1.34. Baricitinib - EMEA-001220-PIP05-19

Treatment of systemic lupus erythematosus

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.35. Mavorixafor - EMEA-002490-PIP01-18

Treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome / Treatment of WHIM syndrome in paediatric patients aged 6 years and above.

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.36. Polymyxin B - EMEA-002595-PIP01-19

Treatment of infections due to aerobic Gram-negative bacteria

Day 30 discussion

Infectious Diseases

3.1.37. Zoliflodacin - EMEA-002599-PIP01-19

Treatment of gonococcal infection / Treatment of uncomplicated gonorrhoea

Day 30 discussion

Infectious Diseases

3.1.38. EMEA-002572-PIP01-19

Chromosome 15q duplication syndrome / cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder / Treatment of seizures associated with chromosome 15q duplication syndrome / Treatment of seizures associated with CDKL5 deficiency disorder

Day 30 discussion

Neurology

3.1.39. Belantamab mafodotin - Orphan - EMEA-002468-PIP04-19

GlaxoSmithKline Trading Services; Treatment of multiple myeloma

Day 30 discussion

Oncology

3.1.40. Infigratinib - EMEA-002594-PIP01-19

Cholangiocarcinoma

Day 30 discussion

Oncology

3.1.41. Adeno-associated viral vector serotype 8 containing the human RPGR gene - Orphan - EMEA-002601-PIP01-19

Nightstar Europa Limited; Treatment of X-linked retinitis pigmentosa

Day 30 discussion

Ophthalmology

3.1.42. Difelikefalin - EMEA-002565-PIP01-19

Chronic kidney disease (CKD)-associated pruritus

Day 30 discussion

Other

3.1.43. Obidoxime chloride / atropine sulfate - EMEA-002570-PIP01-19

Organophosphate nerve agent poisoning

Day 30 discussion

Other

3.1.44. Fexapotide triflutate - EMEA-002598-PIP01-19

Treatment of patients with benign prostatic hyperplasia (BPH)

Day 30 discussion

Uro-nephrology

3.1.45. Recombinant hepatitis B vaccine - EMEA-002157-PIP01-17

Prevention of infection of hepatitis B virus / Secondary immunization of non-responder (anti-HBs levels< 10 mIU/mL) or hypo-responder (anti-HBs levels 10-99 mIU/mL) children age 2-18 years old to prior immunization against hepatitis B virus (HBV) infection / Primary active immunization of children from birth to 18 years old for the prevention of hepatitis B infection

Day 30 discussion

Vaccines

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

No items.

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Sacubitril / valsartan - EMEA-000316-PIP02-11-M04

Novartis Europharm Ltd.; Heart Failure / Treatment of heart failure

Day 30 discussion

Cardiovascular Diseases

3.3.2. Ticagrelor - EMEA-000480-PIP01-08-M12

AstraZeneca AB; Thromboembolic events (children), acute coronary syndrome, history of myocardial infarction / Reduction in occurrence of vaso-occlusive crises in paediatric patients with sickle cell disease

Day 30 discussion

Cardiovascular Diseases / Haematology-Hemostaseology

3.3.3. Liquid ethanolic extract 30 per cent (w/w) of *Allium cepa* L. (fresh bulb) and *Citrus limon* (L.) *Burm. f*. (fresh fruit), *Paullinia cupana Kunth*, *Theobroma cacao* L. - EMEA-001835-PIP01-15-M04

LEGACY HEALTHCARE; Treatment of alopecia

Day 30 discussion

Dermatology

3.3.4. 2-hydroxypropyl-ß-cyclodextrin (HP-ß-CD) - Orphan - EMEA-001866-PIP01-15-M04

Mallinckrodt Pharmaceuticals Ireland Ltd; Treatment of Niemann-Pick disease, type C

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.5. Empagliflozin - EMEA-000828-PIP04-16-M03

Boehringer Ingelheim International GmbH; Treatment of type 1 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

Novo Nordisk A/S; Treatment of obesity

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

Roche Registration GmbH; Treatment of ulcerative colitis/ Treatment of Crohn's disease / Treatment of moderately to severely active Crohn's disease / Treatment of moderately to severely active ulcerative colitis

Day 30 discussion

Gastroenterology-Hepatology

3.3.8. Linaclotide - EMEA-000927-PIP01-10-M04

Allergan Pharmaceuticals International Limited; Functional constipation in children

Day 30 discussion

Gastroenterology-Hepatology

3.3.9. Odevixibat - Orphan - EMEA-002054-PIP01-16-M01

Albireo AB; Progressive familial intrahepatic cholestasis (PFIC)

Day 30 discussion

Gastroenterology-Hepatology

3.3.10. Ferric maltol - EMEA-001195-PIP01-11-M04

Norgine BV; Iron deficiency anaemia / Treatment for iron deficiency anaemia (IDA)

Day 30 discussion

Haematology-Hemostaseology

3.3.11. Lonoctocog alfa - EMEA-001215-PIP01-11-M07

CSL Behring GmbH; Haemophilia A

Day 30 discussion

Haematology-Hemostaseology

3.3.12. Upadacitinib - EMEA-001741-PIP01-14-M02

AbbVie Ltd; Treatment of chronic idiopathic arthritis / Treatment of juvenile idiopathic arthritis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.13. Ustekinumab - EMEA-000311-PIP03-11-M05

Janssen-Cilag International NV; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondyloarthritis, psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA)) / Treatment of juvenile idiopathic arthritis (juvenile psoriatic arthritis (jPsA))

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.14. Lamivudine (3TC) / dolutegravir (DTG) - EMEA-001940-PIP01-16-M02

ViiV Healthcare BV; Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.3.15. Nirsevimab - anti-respiratory syncytial virus human IgG1κ monoclonal antibody - EMEA-001784-PIP01-15-M01

AstraZeneca AB; Prevention of respiratory syncytial viral infections

Day 30 discussion

Infectious Diseases

3.3.16. Pretomanid - Orphan - EMEA-002115-PIP01-17-M01

Global Alliance for TB Drug Development; Treatment of multi-drug-resistant tuberculosis

Day 30 discussion

Infectious Diseases

3.3.17. Arimoclomol citrate - Orphan - EMEA-001748-PIP01-15-M02

Orphazyme A/S; Treatment of Niemann-Pick disease, Type C

Day 30 discussion

Neurology

3.3.18. Ataluren - Orphan - EMEA-000115-PIP01-07-M10

PTC Therapeutics International, Limited; Treatment of dystrophinopathy ICD-10: G71.0 / Muscular dystrophy [of Duchenne and Becker] / Treatment of nonsense-mutation dystrophinopathy

Day 30 discussion

Neurology

3.3.19. Brivaracetam - Orphan - EMEA-000332-PIP01-08-M14

UCB Pharma S.A.; Treatment of neonatal seizures / Treatment of epilepsy with partial onset seizures / Treatment of paediatric patients with partial onset seizures / Treatment of neonatal seizures with adjunctive administration of brivaracetam

Day 30 discussion

Neurology

3.3.20. Onasemnogene abeparvovec - Orphan - EMEA-002168-PIP01-17-M02

AveXis Netherlands B.V.; Treatment of spinal muscular atrophy / Treatment of spinal muscular atrophy Type 1

Day 30 discussion

Neurology

3.3.21. Risdiplam - Orphan - EMEA-002070-PIP01-16-M03

Roche Registration GmbH; Treatment of spinal muscular atrophy

Day 30 discussion

Neurology

3.3.22. Cabozantinib - Orphan - EMEA-001143-PIP01-11-M02

Ipsen Pharma; Treatment of malignant solid tumours

Day 30 discussion

Oncology

3.3.23. Cobimetinib - EMEA-001425-PIP01-13-M04

Roche Registration GmbH; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) with Ras, Raf or MEK pathway activation / Treatment of children with a paediatric solid malignant tumour with known or expected Ras, Raf or MEK pathway activation, at first relapse or refractory to initial treatment

Day 30 discussion

Oncology

3.3.24. Larotrectinib - Orphan - EMEA-001971-PIP02-16-M02

Bayer AG; Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms) / Treatment of paediatric patients from birth to less than 18 years of age with advanced solid tumours harbouring an NTRK fusion

Day 30 discussion

Oncology

3.3.25. Pazopanib - EMEA-000601-PIP01-09-M06

Novartis Europharm Limited; Ewing sarcoma family of tumours /Rhabdomyosarcoma / Non-rhabdomyosarcoma soft tissue sarcoma / Treatment of paediatric patients with rhabdomyosarcoma / Treatment of paediatric patients with Ewing sarcoma family of tumours / Treatment of paediatric patients with non-rhabdomyosarcoma soft tissue sarcoma

Day 30 discussion

Oncology

3.3.26. Tisagenlecleucel - Orphan - EMEA-001654-PIP02-17-M01

Novartis Europharm Limited; Mature B-cell neoplasm / Treatment of paediatric patients with CD19+ relapsed or refractory mature B-cell non-Hodgkin's lymphoma

Day 30 discussion

Oncology

3.3.27. Human thrombin / human fibrinogen - EMEA-001149-PIP01-11-M05

Omrix Biopharmaceuticals N.V.; Treatment of cerebrospinal fluid leakage resulting from a surgical procedure / Treatment of haemorrhage resulting from a surgical procedure / Indicated for suture line sealing in dura mater closure / Indicated for supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis / Indicated for supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis.

Day 30 discussion

Other

3.3.28. Lomitapide - EMEA-001124-PIP01-10-M04

Amryt Pharmaceuticals DAC; Treatment of heterozygous and homozygous familial hypercholesterolaemia / Treatment of homozygous familial hypercholesterolaemia, Treatment of heterozygous familial hypercholesterolemia

Day 30 discussion

Other

3.3.29. *Dermatophagoides farinae / Dermatophagoides pteronyssinus* - EMEA-001258-PIP01-11-M05

ALK-Abelló A/S; Treatment of allergic rhinitis / Treatment of asthma / Indicated in house

dust mite allergic asthma / Indicated in house dust mite allergic rhinitis

Day 30 discussion

Pneumology - Allergology

3.3.30. Fevipiprant - EMEA-001315-PIP02-16-M02

Novartis EuroPharm Limited; Asthma / Treatment of uncontrolled persistent asthma

Day 30 discussion

Pneumology - Allergology

3.3.31. Finerenone - EMEA-001623-PIP01-14-M03

Bayer AG; Chronic kidney disease / Treatment of chronic kidney disease associated with proteinuria in addition to a therapy with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)

Day 30 discussion

Uro-nephrology

3.3.32. Influenza virus surface antigens (haemagglutinin) of strain A (H1N1) / influenza virus surface antigens (haemagglutinin) of strain A (H3N2) / influenza virus surface antigens (haemagglutinin) of strain B (Victoria lineage) / influenza virus surface antigens (haemagglutinin) of strain B (Yamagata lineage) - EMEA-002027-PIP02-17-M01

Adimmune Corporation; Prevention of influenza infection

Day 30 discussion

Vaccines

3.3.33. Outer membrane vesicles (OMV) from neisseria meningitidis serogroup B strain NZ98/254 measured as amount of total protein containing the PorA P1.4 / Recombinant neisseria meningitidis serogroup B fHbp fusion protein / Recombinant neisseria meningitidis serogroup B NadA protein / Recombinant neisseria meningitidis serogroup B NHBA fusion protein - EMEA-000139-PIP01-07-M03

GSK Vaccines S.r.l.; Prevention of meningococcal meningitis

Day 30 discussion

Vaccines

3.3.34. Prepandrix: A/Indonesia/05/2005 (H5N1) like strain used / Adjupanrix: split influenza virus, inactivated, containing antigen: A/VietNam/1194/2004 (H5N1) like strain used - EMEA-000160-PIP01-07-M05

GlaxoSmithKline Biologicals SA; Prevention of influenza infection

Day 30 discussion

Vaccines

4. Nominations

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 20 August 2019 for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

No items

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.2. Ongoing Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.3. Final Scientific Advice (Reports and Scientific Advice letters)

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6. Discussion on the applicability of class waivers

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

6.1.1. NTHi-Mcat vaccine - EMEA-05-2019

GlaxoSmithKline Biologicals SA; All classes of medicinal products for treatment of chronic obstructive pulmonary disease (COPD) (excluding chronic lung diseases associated with long-term airflow limitation, such as asthma, bronchopulmonary dysplasia, primary cilia dyskinesia, obstructive lung disease related to graft-versus-host disease after [bone-marrow] transplantation) / Reduction of exacerbations of chronic obstructive pulmonary disease (COPD) in patients with a history of exacerbations

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was not confirmed because the product is intended for active immunization to prevent infections due to targeted bacterial pathogens, so that reduction in acute exacerbations of chronic obstructive pulmonary disease (COPD) in patients with a history of exacerbations can be achieved. The product mode of action is to induce targeted pathogens-specific protective immunity and is not expected to have direct action on COPD.

Other potential paediatric interests of this medicine suggested by PDCO: children vulnerable to nontypeable *Haemophilus influenzae* (NTHi) and *Moraxella catarrhalis* (Mcat) infections such as paediatric patients with cystic fibrosis.

6.1.2. Pertuzumab/trastuzumab fixed dose combination - EMEA-08-2019

Roche Registration GmbH; The class of HER - / Epidermal growth factor-receptor antibody medicinal products for treatment of breast malignant neoplasms. Early breast cancer: neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer at high risk of recurrence in combination with chemotherapy / Adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence in combination with chemotherapy. Metastatic breast cancer: treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease, for use in combination with docetaxel

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: none identified at this stage.

6.1.3. Acumapimod - EMEA-09-2019

Mereo BioPharma Ireland Limited; All classes of medicinal products for treatment of chronic obstructive pulmonary disease (COPD) (excluding chronic lung diseases associated with long-term airflow limitation, such as asthma, bronchopulmonary dysplasia, primary cilia dyskinesia, obstructive lung disease related to graft versus host disease after [bone-marrow] transplantation) / Treatment of acute exacerbations of COPD

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: none identified at this stage.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

7.1.1. Icosapent ethyl - EMEA-001300-PIP01-12

NDA Regulatory Science Ltd; Treatment of hypertriglyceridemia

Proposed indication: to reduce the risk of cardiovascular death, myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization as an adjunct to statin therapy in adult patients with elevated triglyceride levels (TG ⩾135 mg/dL) and other risk factors for cardiovascular disease

Summary of committee discussion:

The PDCO agreed with the Applicant that the proposed indication, 'to reduce the risk of cardiovascular death, myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization as an adjunct to statin therapy in adult patients with elevated triglyceride levels (TG ≥135 mg/dL) and other risk factors for cardiovascular disease', is included within the PIP condition 'treatment of hypertriglyceridemia' listed in the Agency Decision.

7.1.2. Fc- and CDR-modified humanized monoclonal antibody against C5 - EMEA-001943-PIP01-16-M01

Alexion Pharma GmbH; Treatment of atypical haemolytic uremic syndrome

Proposed indication: Treatment of patients with complement-mediated thrombotic microangiopathy (TMA)

Summary of committee discussion:

The committee was of the view that the proposed indication 'treatment of patients with complement-mediated thrombotic microangiopathy (TMA)', does not fall under the scope of the above mentioned Decision, as the indication was not considered to be covered by the condition 'treatment of atypical haemolytic uremic syndrome' listed in the Agency Decision.

7.1.3. Ticagrelor - EMEA-000480-PIP01-08-M11

AstraZeneca AB; Prevention of thromboembolic events

Proposed indication: Ticagrelor is indicated for the prevention of stroke and death in patients with acute ischaemic stroke or transient ischaemic attack

Cardiovascular Diseases / Haematology-Hemostaseology

Summary of committee discussion:

The PDCO agreed with the Applicant that the proposed indication is included within the PIP condition 'prevention of thromboembolic events'.

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. Update on PDCO member(s)/alternate(s) mandate status

The PDCO Committee noted the nomination of Melinda Sobor as the new alternate for Hungary, Martine Trauffler as the new alternate for Luxembourg and Simona Badoi as the new alternate for Romania, all three nominated within CHMP.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The PDCO members were informed about the final CHMP Opinions on medicinal products with recommended paediatric indications adopted in May 2019. These included Cufence (trientine dihydrochloride).

The list of procedures with paediatric indications to be evaluated by the CHMP, starting in May 2019, was presented to the PDCO members.

9.2.2. EMA Scientific Committees – Timing for Chair elections

Summary of committee discussion:

The EMA Secretariat informed the Committee on the timing for Chair's and vice-Chair's elections for 2019. The PDCO Chair election is scheduled in July 2019 and the PDCO vice-Chair election in October 2019.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: Draft manuscript on the non-clinical CNS project

PDCO member: Karen van Malderen

Summary of committee discussion:

The outcome of an evaluation of juvenile animal studies for paediatric CNS-targeted compounds was presented.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require Formulation Working Group evaluation and discussion.

9.3.3. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of committee discussion:

The Chair of the Non-clinical Working Group identified the products which will require Non-clinical Working Group (NCWG) evaluation and discussion.

9.4. Cooperation within the EU regulatory network

9.4.1. CTFG: Recommendation Paper on the Initiation and Conduct of Complex Clinical Trials

CTFG Chair: Ann Marie Janson Lang; Elke Stah

Summary of committee discussion:

The Clinical Trials Facilitation and Coordination Group (CTFG) Chair presented the Recommendation Paper on the Initiation and Conduct of Complex Clinical Trials. It was also the opportunity to discuss how to further strengthen collaboration between the CTFG and the PDCO.

9.5. Cooperation with International Regulators

9.5.1. Report from the Paediatric Cluster Teleconference

Summary of committee discussion:

The Committee was informed about the discussions at the Paediatric Cluster teleconference on 20 June 2019.

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No items

9.7. PDCO work plan

No items

9.8. Planning and reporting

9.8.1. Marketing authorisation applications (MAA) forecast for 2019 – planning update dated Q2 2019

Summary of committee discussion:

The EMA Business Analysis & Forecasting presented to PDCO for information a quarterly updated report on marketing authorisation applications planned for submission (the business 'pipeline').

9.8.2. A first perspective on the impact of the review of the class waiver list in July 2015

Summary of committee discussion:

A perspective was given on the impact of the revision of the class waiver list on oncology PIPs.

9.8.3. Strategic Review and Learning Meeting (SRLM) under the Romanian Presidency held in Malta on 13-14 June 2019 - Report to the Committee

PDCO topic leaders: Dirk Mentzer, Dana Gabriela Marin, Herbert Lenicker

Summary of committee discussion:

The PDCO was provided with feedback from the SRLM held on 13-14 June 2019 in Malta. Some topics from the EMA/EC Paediatric Action Plan were discussed. A shorter re-discussion within the PDCO plenary with full attendance will be needed in the coming months for some topics, to agree on the way forward: unmet medical needs, Duchenne Muscular Dystrophy – possibly with some SAWP members and/or patients'

representatives, modelling and simulation / extrapolation, Clinical Trials Authorisation – re-discussion to link with interactions with CTFG.

10. Any other business

No items

11. Breakout sessions

11.1.1. Paediatric oncology

Summary of committee discussion:

The break-out session was cancelled.

11.1.2. Neonatology

Summary of committee discussion:

The Neonatology breakout session discussed upcoming and ongoing PIPs and Scientific Advices involving the neonatal population.

11.1.3. Inventory

Summary of committee discussion:

The inventory group discussed the assessment of unmet need as well as organisational matters.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 25–28 June 2019 meeting

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	N/A
Karl-Heinz Huemer	Member	Austria	No interests declared	N/A
Koenraad Norga	Member (Vice-Chair)	Belgium	When chairing the meeting: To be replaced for discussions, final deliberations and voting When not chairing the meeting: No participation in final deliberations and voting	Recombinant human monoclonal antibody to GM-CSF - EMEA-001882-PIP02-16-M01 Belantamab mafodotin - Orphan - EMEA-002468-PIP04-19 - Discussion EMEA-000160-PIP01-07-M05 Niraparib - Orphan - EMEA-002268-PIP02-18 Anti PD-1 monoclonal antibody - EMEA-002463-PIP01-18
Karen Van Malderen	Alternate	Belgium	No interests declared	N/A
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	None
Georgios Savva	Member	Cyprus	No interests declared	N/A
Tereza Bazantova	Member	Czech Republic	No interests declared	N/A
Kirstine Moll Harboe	Member	Denmark	No interests declared	N/A
Irja Lutsar	Member	Estonia	No interests declared	N/A
Jana Lass	Alternate	Estonia	No interests declared	N/A
Ann Marie Totterman	Member	Finland	No interests declared	N/A
Sylvie Benchetrit	Member	France	No interests declared	N/A
Dominique Ploin	Alternate	France	No interests declared	N/A
Sabine Scherer	Member	Germany	No interests declared	N/A
Yuansheng Sun	Alternate	Germany	No interests declared	N/A
Eleni Katsomiti	Member	Greece	No interests declared	N/A
Anastasia Mountaki	Alternate	Greece	No interests declared	N/A

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	N/A
Brian Aylward	Member	Ireland	No interests declared	N/A
Sara Galluzzo	Member	Italy	No interests declared	N/A
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	None
Sigita Burokiene	Member	Lithuania	No interests declared	N/A
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	N/A
Herbert Lenicker	Alternate	Malta	No interests declared	N/A
Maaike van Dartel	Member	Netherlands	No interests declared	N/A
Siri Wang	Member	Norway	No interests declared	N/A
Marek Migdal	Member	Poland	No interests declared	N/A
Helena Fonseca	Member	Portugal	No interests declared	N/A
Hugo Tavares	Alternate	Portugal	No interests declared	N/A
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	N/A
Peter Sisovsky	Member	Slovakia	No interests declared	N/A
Peter Szitanyi	Alternate	Slovakia	No interests declared	N/A
Stefan Grosek	Member	Slovenia	No interests declared	N/A
Fernando de Andrés Trelles	Member	Spain	No interests declared	N/A
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	N/A
Ninna Gullberg	Member	Sweden	No interests declared	N/A
Eva Agurell	Alternate	Sweden	No interests declared	N/A
Angeliki Siapkara	Member	United Kingdom	No interests declared	N/A
Fernando Cabanas	Member	Healthcare Professionals' Representative	No participation in final deliberations and voting on:	Nirsevimab (anti-respiratory syncytial virus human IgG1κ monoclonal antibody - MEDI8897) - EMEA-001784-PIP01-15-M01
Jorrit Gerritsen	Alternate	Healthcare Professionals' Representative	No interests declared	N/A
Francesca Rocchi	Member	Healthcare Professionals'	No restrictions applicable to this	None

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
		Representative	meeting	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	N/A
Günter Karl-Heinz Auerswald	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	None
Paola Baiardi	Alternate	Patients' Organisation Representative	No restrictions applicable to this meeting	None
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	N/A
Maria Estela Moreno Martin	Expert - in person*	Spain - AGEMED/AEMPS	No interests declared	N/A
Anna Joo	Expert - in person*	Sweden - MPA	No restrictions applicable to this meeting	None
Fabienne Gaugazova	Expert - in person*	Sweden - MPA	No participation in discussion, final deliberations and voting on:	Larotrectinib - Orphan - EMEA-001971-PIP02-16-M02 Finerenone - EMEA-001623-PIP01-14-M03
Romaldas Mačiulaitis	Expert - in person*	Lithuania		Baloxavir marboxil - EMEA-002440-PIP01-18 A fully human, IgG2 mAb (MSTT1041A / RO7187807) - EMEA-002433-PIP01-18 Etrolizumab - EMEA-001434-PIP01-13-M02 Risdiplam - Orphan - EMEA-002070-PIP01-16-M03 Cobimetinib - EMEA-001425-PIP01-13-M04 Pertuzumab/trastuzumab fixed dose combination - EMEA-08-2019
Kristina Dunder	Expert - in person*	Sweden	No interests declared	N/A
Johann Lodewijk Hillege	Expert - in person*	Netherlands	No interests declared	N/A
Roel Bolt	Expert - in person*	Netherlands	No interests declared	N/A
Ann Marie Janson Lang	Expert - in person*	CTFG Chair	No interests declared	N/A

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Jan Willem van der Laan	Expert - via telephone*	Netherlands	No interests declared	N/A
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the Applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website:
www.ema.europa.eu/